

Poster Number	First name	Last name	Abstract Title
1	Carole	Bartoo	Implementation of the Shed-MEDS Deprescribing Intervention for Persons with Dementia in Assisted Living: Successes and challenges
2	Lily	Bessette	Older adults' use of heart failure exacerbating medications before and after heart failure hospitalizations
3	Adara	Bochanis	Trajectories of Medication Use Prior to Death in US Nursing Home Residents with Dementia
4	Huai	Cheng	Integrating ChatGPT to Reducing Polypharmacy Workshop: An Innovative Curriculum
5	Andrea	Daddato	Engaging patients and caregivers in co-design of a patient portal-based deprescribing intervention
6	Kieran	Dalton	Development of a prescribing cascade classification framework: a modified nominal group technique study
7	James	Deardorff	Household wealth and use of problematic medications in persons with dementia: Role of comorbidities and caregivers
8	Christine	Eisenhower	Reducing Anticholinergic Medication Use in PACE Participants through a Pharmacist Quality Initiative
9	Jennifer	Esch	Assessment of Interventions after Emergency Department Pharmacist Review of AGS Beers Criteria® Medications
10	Terri	Fried	Development of a Framework for Deprescribing Communication in the Clinical Encounter,
11	Constance	Fung	Cognition following benzodiazepine receptor agonist deprescribing
12	Julia	Gallagher	Hiding in plain sight: Sarcopenic obesity, cystatin C, and management of polypharmacy
13	Matthew	Growdon	Decision-making and downstream consequences of the gabapentinoid–diuretic prescribing cascade
14	Katherine	Holzer	Perioperative Exposure to Potentially Inappropriate Medications and Postoperative Outcomes in Older Adults Undergoing Surgery

15	Catherine	Hwang	Changes in the Use of Oncology Medications after Withdrawal of Accelerated Approval
16	Kenya	le	Association Between Patients' Perceptions of Deprescribing and Health Outcomes: A Prospective Cohort Study
17	Changgi	Jung	Bridging the Gap in Deprescribing: Implementing the 'Is It Really A Concern?' Tool in Geriatric Care
18	Katharina	Jungo	What role should pharmaceutical and MedTech companies play in deprescribing?
19	Katharina	Jungo	Reporting of Sociodemographic and Clinical Characteristics in US-Based Randomized Clinical Trials of Deprescribing Interventions for Older Adults
20	Lisa	LaRowe	Reducing Risk for Problematic Substance Use during Opioid Deprescribing: A Qualitative Study
21	Julie	Lauffenburger	Deprescribing in patients living with dementia with caregiver and provider nudges: Ongoing feasibility trial
22	Jiha	Lee	Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
23	David	Lynch	A Standardized Protocol to Facilitate Deprescribing and De-escalation of PIMs for Hospitalized Older Adults
24	Christopher	Miller	Digital Cognitive Behavioral Therapy for Generalized Anxiety Disorder- Impact on Medication and Healthcare Utilization and Costs in Adults
25	Christopher	Miller	Digital Cognitive Behavioral Therapy for Insomnia- Impact on Medication and Healthcare Utilization and Costs in Adults

26	Christopher	Miller	Impact of Digital CBT for Insomnia in Clinical Practice- Reduced Medication Fills and Medical Visits
27	Venoos	Moshayedi	Interprofessional Collaboration in Dementia Care: Polypharmacy Leading to Misdiagnosed Dementia
28	Venoos	Moshayedi	Polypharmacy and High-Risk Medications in Older Adults: A Case Review
29	Joshua	Niznik	Exploring Patient and Caregiver Goals of Care and Medication Use Among Veteran Nursing Home Residents with Dementia
30	Jonathan	Norton	Identifying adverse drug withdrawal events after discontinuation of an oral diabetes medication in a retrospective cohort
31	Helen	Omuya	Developing the Deprescribing Evaluation and Quality Improvement Instrument: Expert Validation and Refinement of a Tool for Assessing Experiences of Older Adults with Deprescribing Interventions
32	Andrew	Pagliocchini	Feasibility and Acceptability of a Pragmatic, Pharmacist-Led Telehealth Deprescribing Intervention for People with Dementia in Primary Care
33	Rosalphie	Quiles	Recruitment and Attrition in a Deprescribing Trial for People with Dementia
34	Emily	Reeve	Optimising implementability of deprescribing recommendations: perspectives of guideline end-users
35	Emily	Reeve	International perspectives on the language, content and format of deprescribing recommendations
36	Tatiana	Requijo	Developing Educational Materials for a Deprescribing Intervention in Aging World Trade Center Responders
37	Jaime	Rosenthal	Geriatrics Deprescribing eConsults to Optimize Medications Among Older Adults in Primary Care
38	Lyanne	Santana Khoury	TIA, Falls and Fracture? A Complex Case of Polypharmacy on a Geriatric Co-Managed Service

39	Orla	Sheehan	Challenges Identifying Adverse Drug Withdrawal Events: Real World Examples from Electronic Health Records
40	Caroline	Sloan	Association between polypharmacy and physical function in middle-aged adults: Findings from the CARDIA Function study
41	Samuel	Terman	Development of a rapid screener to elicit patient preferences for antiseizure medication discontinuation
42	Carolyn	Thorpe	Discontinuation of Aspirin for Primary Prevention in Veterans Affairs Nursing Home Residents with Dementia
43	Antalique	Tran	Clinical Quality Measures May Hinder Deprescribing: A Qualitative Study
44	Nha	Tran	Using the COM-B Model to Examine Willingness to Deprescribe among Older Adults with Diabetes
45	Hannah	VanTruong	The Impact of Documented Pharmacist Recommendations for Deprescribing Psychotropic Medications in Older Adults
46	Chinmayi	Venkatram	Polypharmacy and Frailty among Aging World Trade Center Responders
47	Alexandria	Wahler	Patient and Caregiver Perspectives on Medication Safety for Older Adults During Transitions of Care
48	Robert	Wahler	Incidence of central nervous system prescribing cascades in a Western New York Older Persons